CoChat

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia

Open access
Cherry, Evan M., Abbott, Diana, Amaya, Maria, McMahon, Christine, Schwartz, Marc, Rosser, Julie, Sato, Audrey, Schowinsky, Jeffrey, Inguva, Anagha, Minhajuddin, Mohd, Pei, Shanshan, Stevens, Brett, Winters, Amanda, Jordan, Craig T., Smith, Clayton, Gutman, Jonathan A., Pollyea, Daniel A. · 2021 · Blood Advances
Cited by 170

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy (IC). Some patients who are IC candidates instead receive ven/aza. We retrospectively analyzed patients with newly diagnosed AML who received ven/aza (n = 143) or IC (n = 149) to compare outcomes, seek variables that could predict response to 1 therapy or the other, and ascertain whether treatment recommendations could be refined. The response rates were 76.9% for ven/aza and 70.5% for IC. The median overall survival (OS) was 884 days for IC compared with 483 days for ven/aza (P = .0020). A propensity-matched cohort was used to compare outcomes in the setting of equivalent baseline variables, and when matched for age, biological risk, and transplantation, the median OS was 705 days for IC compared with not reached for ven/aza (P = .0667). Variables that favored response to ven/aza over IC included older age, secondary AML, and RUNX1 mutations. AML M5 favored response to IC over ven/aza. In the propensity-matched cohort analyzing OS, older age, adverse risk, and RUNX1 mutations favored ven/aza over IC, whereas intermediate risk favored IC over ven/aza. In conclusion, patients receiving IC have improved OS compared with those receiving ven/aza. However, in a propensity-matched cohort of patients with equivalent baseline factors, there was a trend toward favorable OS for ven/aza. Specific variables, such as RUNX1 mutations, reported here for the first time, can be identified that favor ven/aza or IC, helping to guide treatment decisions for patients who may be eligible candidates for either therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2021005538

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 170

Metadata

Authors
Cherry, E. M., Abbott, D., Amaya, M., McMahon, C., Schwartz, M., Rosser, J., Sato, A., Schowinsky, J., Inguva, A., Minhajuddin, M., Pei, S., Stevens, B., Winters, A., Jordan, C. T., Smith, C., Gutman, J. A., & Pollyea, D. A.
Venue
Blood Advances
Published
2021-12-20
Volume
5
Issue
24
Pages
5565-5573
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W3202266999
Cited by
170
References
11
FWCI
16.79
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. https://app.cochat.ai/papers/10.1182/bloodadvances.2021005538
The paper
Cherry, E. M., Abbott, D., Amaya, M., McMahon, C., Schwartz, M., Rosser, J., Sato, A., Schowinsky, J., Inguva, A., Minhajuddin, M., Pei, S., Stevens, B., Winters, A., Jordan, C. T., Smith, C., Gutman, J. A., & Pollyea, D. A. (2021). Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Advances. https://doi.org/10.1182/bloodadvances.2021005538

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.